Jasper Therapeutics Inc expected to post a loss of $1.61 a share - Earnings Preview

Jasper Therapeutics

04/03/2024 11:06

* Jasper Therapeutics Inc  JSPR.OQ   JSPR.O  is expected
to show
no change in quarterly revenue when it reports  results on March
6 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Jasper Therapeutics Inc
is for
a loss of $1.61 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Jasper
Therapeutics Inc is $67.50​, above​ its last closing price
of $22.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.53       -1.55      -1.60     Missed  -3.1
 Jun. 30 2023  -1.81       -1.50      -1.50     Met     -0.1
 Mar. 31 2023  -1.64       -1.62      -1.60     Beat    1.5​
 Jan. 1 0001   -3.51       -3.60      -3.60     Met     0
 ​​Sep.        -3.40       -3.42      -3.20     Beat    6.6
 30 2022                                                
 Jun. 30 2022  -3.23       -3.13      -2.90     Beat    7.4​
 Mar. 31 2022  -3.49       -3.50      -0.60     Beat    82.9
 Dec. 31 2021  -2.54       -3.43      -7.90     Missed  -130
 This summary was machine generated March 4 at 11:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)